Jan-Peter van Wieringen1, Martin C Michel2, Henk M Janssen3, Anton G Janssen4, Philip H Elsinga5, Jan Booij1. 1. Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105, AZ, The Netherlands. 2. Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany. 3. SyMO-Chem BV, Eindhoven, The Netherlands. 4. GE Healthcare, Eindhoven, The Netherlands. 5. Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: Dopamine D2/3 receptor (D2/3R) agonist radiopharmaceuticals are considered superior to antagonists to detect dopamine release, e.g. induced by amphetamines. Agonists bind preferentially to the high-affinity state of the dopamine D2R, which has been proposed as the reason why agonists are more sensitive to detect dopamine release than antagonist radiopharmaceuticals, but this theory has been challenged. Interestingly, not all agonists similarly activate the classic cyclic adenosine mono phosphate (cAMP) and the ?-arrestin-2 pathway, some stimulate preferentially one of these pathways; a phenomenon called biased agonism. Because these pathways can be affected separately by pathologies or drugs (including dopamine releasers), it is important to know how agonist radiotracers act on these pathways. Therefore, we characterized the intracellular signalling of the well-known D2/3R agonist radiopharmaceuticals NPA and PHNO and of several novel D2/3R agonists. METHODS: cAMP accumulation and ?-arrestin-2 recruitment were measured on cells expressing human D2R. RESULTS: All tested agonists showed (almost) full agonism in both pathways. CONCLUSIONS: The tested D2/3R agonist radiopharmaceuticals did not exhibit biased agonism in vitro. Consequently, it is likely that drugs (including psychostimulants like amphetamines) and/or pathologies that influence the cAMP and/or the ?-arrestin-2 pathway may influence the binding of these radiopharmaceuticals.
BACKGROUND:Dopamine D2/3 receptor (D2/3R) agonist radiopharmaceuticals are considered superior to antagonists to detect dopamine release, e.g. induced by amphetamines. Agonists bind preferentially to the high-affinity state of the dopamineD2R, which has been proposed as the reason why agonists are more sensitive to detect dopamine release than antagonist radiopharmaceuticals, but this theory has been challenged. Interestingly, not all agonists similarly activate the classic cyclic adenosine mono phosphate (cAMP) and the ?-arrestin-2 pathway, some stimulate preferentially one of these pathways; a phenomenon called biased agonism. Because these pathways can be affected separately by pathologies or drugs (including dopamine releasers), it is important to know how agonist radiotracers act on these pathways. Therefore, we characterized the intracellular signalling of the well-known D2/3R agonist radiopharmaceuticals NPA and PHNO and of several novel D2/3R agonists. METHODS:cAMP accumulation and ?-arrestin-2 recruitment were measured on cells expressing humanD2R. RESULTS: All tested agonists showed (almost) full agonism in both pathways. CONCLUSIONS: The tested D2/3R agonist radiopharmaceuticals did not exhibit biased agonism in vitro. Consequently, it is likely that drugs (including psychostimulants like amphetamines) and/or pathologies that influence the cAMP and/or the ?-arrestin-2 pathway may influence the binding of these radiopharmaceuticals.
Authors: Nicholas Seneca; Sjoerd J Finnema; Lars Farde; Balázs Gulyás; Håkan V Wikström; Christer Halldin; Robert B Innis Journal: Synapse Date: 2006-04 Impact factor: 2.562
Authors: Nathalie Ginovart; Laurent Galineau; Matthaeus Willeit; Romina Mizrahi; Peter M Bloomfield; Philip Seeman; Sylvain Houle; Shitij Kapur; Alan A Wilson Journal: J Neurochem Date: 2006-04-05 Impact factor: 5.372
Authors: T de Paulis; Y Kumar; L Johansson; S Rämsby; L Florvall; H Hall; K Angeby-Möller; S O Ogren Journal: J Med Chem Date: 1985-09 Impact factor: 7.446
Authors: Ningning Guo; Wen Guo; Michaela Kralikova; Man Jiang; Ira Schieren; Raj Narendran; Mark Slifstein; Anissa Abi-Dargham; Marc Laruelle; Jonathan A Javitch; Stephen Rayport Journal: Neuropsychopharmacology Date: 2009-12-02 Impact factor: 7.853
Authors: Vladimir Shalgunov; Jan-Peter van Wieringen; Henk M Janssen; P Michel Fransen; Rudi A J O Dierckx; Martin C Michel; Jan Booij; Philip H Elsinga Journal: EJNMMI Res Date: 2015-07-25 Impact factor: 3.138